Gilead’s Oncology Drug Recommended for Approval in the EU – Analyst Blog
Close on the heels of the oncology drug Zydelig (idelalisib 150 mg) gaining approval in the U.S., Gilead Sciences ( …read more
Investing and Market Analysis
Will Spain’s Repsol Really Buy Canada’s Talisman Energy? – Analyst Blog
Struggling Canadian energy explorer Talisman Energy Inc. ( TLM ) confirmed days of rumors by announcing that it has been …read more
Will Waste Management (WM) Surprise on Q2 Earnings This Season? – Analyst Blog
Waste Management, Inc ( WM ) is scheduled to report second quarter 2014 results before the opening bell on Jul …read more
Stocks That Are Defying Odds
Today, we’re featuring an article with eight stocks that the author is referring to as “Hercules” stocks. What is a Hercules stock? Well if you… Read More »Stocks That Are Defying Odds
Steven Romick Comments on Alcoa And Norsk Hydro
We initiated positions in two aluminum companies last fall, Alcoa ( AA ) and Norsk Hydro ( OSL NHY ), …read more
Steven Romick Comments on Jardine Matheson And Jardine Strategic
Crescent Co Portfolio Manager Mark Landecker profiled our investment in the “Jardines” at our FPA Investor Day. These Hong Kong …read more
Ignore the experts; Credit cards can be great for your finances
When you’re trying to get out of debt, get back on financial track, or recover from bankruptcy, chances are you …read more
Liberty Media Down on Senior Note Conversion Rate Adjustment – Analyst Blog
Yesterday, Liberty Media Corp. ( LMCA ) announced a major adjustment to the conversion rate of its 1.375% Cash Convertible …read more
Will NextEra Energy (NEE) Beat Earnings Estimates in Q2? – Analyst Blog
NextEra Energy, Inc. ( NEE ) will release its second quarter 2014 financial results before the opening bell on Jul …read more
Can Illinois Tool (ITW) Deliver Upbeat Results This Quarter? – Analyst Blog
Industrial products and equipments manufacturer, Illinois Tool Works Inc. ( ITW ), is scheduled to report its second quarter 2014 …read more